Upperton Pharma Solutions has proudly been awarded the prestigious Pharma Project of the Year at the Pharma Industry Awards UK 2024, celebrated at the International Convention Centre (ICC) in Birmingham on 18th September. This esteemed event acknowledged excellence within the pharmaceutical and biotech industries, highlighting outstanding achievements across numerous categories.
Celebrating Excellence in the Pharmaceutical Sector
Upperton secured this accolade, competing against well-known finalists Sanofi and Bouygues Energies & Services, for the build, commissioning, and validation of its expansive 50,000-square-foot Trent Gateway development and manufacturing facility. The project received acclaim for its exemplary project management, strategic partnerships with UK supply chains, and remarkable completion time of just 10 months from inception to finalisation.
Significant Expansion with Trent Gateway Facility
The Trent Gateway facility represents a significant milestone in Upperton’s growth, featuring ten GMP manufacturing suites, dedicated quality control laboratories, analytical and formulation development labs, as well as pilot plant facilities. This cutting-edge facility positions Upperton to address the escalating demands of its clients while enhancing its pharmaceutical development services.
Team Effort Recognised
Ian Lafferty, Chief Technical Officer and Project Lead for Trent Gateway, commended the team’s dedication, stating, “This award is the result of 18 months of relentless effort from our team. Constructing a facility of this calibre within 10 months is an exceptional accomplishment. Validating, commissioning, and obtaining MHRA approval has enabled us to develop and manufacture at a new scale for our clients.”
Commitment to Growth and Innovation
Nikki Whitfield, Chief Executive Officer of Upperton, expressed her pride in this achievement: “Being honoured for our Trent Gateway facility is a remarkable milestone. This state-of-the-art development meets the growing demands of our customers and broadens our service offerings along the drug development continuum. The facility meets our clients’ needs in terms of complexity, scale, and potency while complying with all necessary regulatory requirements. The commitment and meticulousness of our team have enabled us to enhance our services, collaborating with the finest talent in the Midlands and beyond. This facility exemplifies our dedication to growth and innovation.”
Recognition of Forward-Thinking Approach
“The Pharma Project of the Year award highlights Upperton’s forward-thinking strategy in partnering with UK supply chains and its expertise in providing cutting-edge solutions for drug development and manufacturing. This accolade further solidifies Upperton’s reputation as a leader in the industry.
Diverse Capabilities of the Trent Gateway Facility
The Trent Gateway facility is designed to develop and manufacture a diverse array of dosage forms, including oral solids, liquids, semi-solids, nasal, and inhaled products. It facilitates early-stage formulation development and supplies clinical trial materials ranging from Phase 1 through Phase 3. The facility’s GMP design, equipment, and containment capabilities are tailored to accommodate larger-scale process trains, supporting batch sizes of up to 250kg.
Unwavering Commitment to Excellence
Upperton’s recognition at the Pharma Industry Awards UK 2024 reflects its unwavering commitment to excellence and innovation in the pharmaceutical sector. As the company continues to expand and enhance its capabilities, it remains dedicated to delivering high-quality solutions to its clients, fostering growth and success within the industry.